ArticleMed (New York, N.Y.)2022

Discovery and intranasal administration of a SARS-CoV-2 broadly acting neutralizing antibody with activity against multiple Omicron subvariants.

J Andrew Duty et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.